Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects
- Autores: Kozin S.1, Barykin E.1, Mitkevich V.1, Makarov A.1
-
Afiliações:
- Engelhardt Institute of Molecular Biology
- Edição: Volume 83, Nº 9 (2018)
- Páginas: 1057-1067
- Seção: Review
- URL: https://journals.rcsi.science/0006-2979/article/view/151713
- DOI: https://doi.org/10.1134/S0006297918090079
- ID: 151713
Citar
Resumo
Drug development for the treatment of Alzheimer’s disease (AD) has been for a long time focused on agents that were expected to support endogenous β-amyloid (Aβ) in a monomeric state and destroy soluble Aβ oligomers and insoluble Aβ aggregates. However, this strategy has failed over the last 20 years and was eventually abandoned. In this review, we propose a new approach to the anti-amyloid AD therapy based on the latest achievements in understanding molecular causes of cerebral amyloidosis in AD animal models.
Palavras-chave
Sobre autores
S. Kozin
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Rússia, Moscow, 119991
E. Barykin
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Rússia, Moscow, 119991
V. Mitkevich
Engelhardt Institute of Molecular Biology
Autor responsável pela correspondência
Email: mitkevich@gmail.com
Rússia, Moscow, 119991
A. Makarov
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Rússia, Moscow, 119991